<DOC>
	<DOCNO>NCT01230918</DOCNO>
	<brief_summary>The objective determine whether 99Technetium-NC100692 uptake patient ACS ( MI ) serve marker scar formation detect contrast-enhanced MRI process myocardial remodelling ischemic insult . Comparison ACS HCM Populations : The primary objective determine whether TcNC100692 image able quantify extent myocardial fibrogenesis occur early post myocardial infarction differs patient hypertrophic cardiomyopathy . The primary hypothesis since fibrogenesis know occur intensely first day week post myocardial infarction , protract , less predictable process HCM , significantly TcNC100692 uptake early post-ACS population HCM population . Control Population : Normal control image allow differentiation uptake myocardium .</brief_summary>
	<brief_title>Study Develop Non-invasive Marker Monitoring Myocardial Fibrosis</brief_title>
	<detailed_description>HCM Population : The primary objective determine whether fibrosis detect MRI 99mTc-NC100692 uptake patient HCM associate . The secondary objective determine whether 99mTc-NC100692 uptake correlate segmental basis fibrosis visualise late Gd-enhancement MRI . The tertiary objective evaluate relationship extent fibrosis assess 99mTc-NC100692 uptake mean longitudinal strain determine speckle track echocardiography . The primary hypothesis increase uptake 99mTc-NC100692 patient HCM fibrosis detect MRI . The secondary hypothesis location extent increase 99mTc-NC100692 uptake correlate localization extent measurement fibrosis Gd-enhanced magnetic resonance imaging . The tertiary hypothesis extent fibrosis assess number segment magnitude 99mTc NC100692 uptake correlate mean longitudinal strain determine speckle track echocardiography . ACS Population : The objective determine whether 99Technetium-NC100692 uptake patient ACS ( MI ) serve marker scar formation detect contrast-enhanced MRI process myocardial remodelling ischemic insult . The primary hypothesis increase uptake 99Technetium-NC100692 patient follow ACS event ( MI ) location extent increase 99Technetium-NC100692 uptake correlate presence extent scar detect contrast-enhanced magnetic resonance imaging . Normal Control Population : Preliminary analysis image HCM population show diffuse , low grade uptake 99Technetium-NC100692 non-hypertrophied myocardial segment . Although entirely unexpected , comparison control image allow quantification low grade fibrosis low grade uptake .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<criteria>HCM Population : Diagnosis HCM define : Interventricular septal thickness great 12 mm 2D echocardiogram , septal : posterior wall thickness measure parasternal long axis view &gt; 1.3 absence secondary cause cardiac hypertrophy aortic stenosis systemic hypertension . Concomitant disease lead myocardial hypertrophy include valvular heart disease uncontrolled hypertension . If HCM prove either presence family history HCM genotyping , patient control hypertension exclude . Documented coronary artery disease include history previous myocardial infarction coronary intervention revascularization . Known diabetic cardiomyopathy . ACS Population : Diagnosis ACS , either NSTEMI determine positive myocardial marker STEMI patient onset symptom 12 hour less presentation STsegment elevation least 1 mm two contiguous limb lead least 2 mm two contiguous precordial lead prehospital 12lead ECGs . Patients undergo 99mTcNC100692 image within 1 week acute myocardial infarction . Patients present acute STEMI secondary occlusive thrombus revascularized coronary artery bypass surgery . Patients know prior history cardiomyopathy cause ( ex . ischemic , hypertrophic , infiltrative , idiopathic dilate ) , precede index referral primary PCI . Hemodynamic instability cardiogenic shock . Normal Control : No clinically significant chronic acute illness determine history , echocardiogram and/or available report . Subjects preexist confound factor , hypertension , diabetes mellitus , hyperlipidemia , CAD , know structural heart disease , leave ventricular dysfunction , previous cerebrovascular event , malignancy , connective tissue inflammatory disease , chronic infection , hepatic renal impairment exclude . Possess abnormal cardiac structure function examination ECHO All population : The subject great equal 18 year age study entry . Before study procedure carry , subject able willing comply study procedure provide sign date informed consent , include permission access medical record . The subject male , female either surgically sterile ( documented bilateral oophorectomy and/or document hysterectomy ) , postmenopausal ( cessation menses 1 year ) , nonlactating , childbearing potential result urine pregnancy test perform administration IMP negative . Hypersensitivity component 99mTcNC100692 injection ( e.g . p aminobenzoate ) . Pregnancy . Unwillingness provide sign inform consent . Creatinine clearance &lt; 30 ml/min .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hypertrophic Cardiomyopathy</keyword>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>Myocardial Fibrosis</keyword>
	<keyword>Fibrogenesis</keyword>
	<keyword>Intimal Hyperplasia</keyword>
	<keyword>Sudden Death</keyword>
	<keyword>avB3 Integrin Expression</keyword>
</DOC>